Table 2 Responses from retina specialists having experience with CSCR management and eplerenone therapy:
From: Real-world practice patterns of eplerenone use for central serous chorioretinopathy
Retinal specialists having experience with eplerenone therapy (n) | 149 | |
|---|---|---|
Availability of PDT in practice (n, %) | No, not available | 94 (63) |
Yes, but difficult to get the drug | 46 (31) | |
Yes, easily available | 9 (6) | |
Effect of VICI trial results on eplerenone usage (n, %) | Yes | 30 (20) |
No | 70 (47) | |
Somewhat | 49 (33) | |
Indication for Eplerenone use (n, %) | Acute | 22 (15) |
Chronic | 86 (58) | |
Both | 41 (27) | |
Laterality consideration for Eplerenone use (n, %) | Unilateral | 6 (4) |
Bilateral | 8 (5) | |
Doesn’t matter | 135 (91) | |
% of patients are/were on eplerenone treatment (n, %) | 0–25 | 92 (62) |
25–50 | 33 (22) | |
50–75 | 12 (8) | |
75–100 | 12 (8) | |
Prescription of Eplerenone in the current practice (n, %) | Yes routinely | 50 (34) |
Only when there is no response to available options | 85 (57) | |
Prescribed earlier, not now | 14 (9) | |
When to prescribe Eplerenone (n, %) | First line | 36 (24) |
Second line as monotherapy | 63 (42) | |
Third line as combination | 17 (11) | |
Desperate situations | 33 (22) | |
Daily Dose of Eplerenone (n, %) | 25 | 19 (13) |
50 | 73 (49) | |
25–50 | 57 (38) | |
Duration of Eplerenone use (n, %) | 0–3 | 137 (92) |
4–6 | 10 (7) | |
> 6 | 2 (1) | |
Satisfaction levels with eplerenone (n, %) | Very satisfied | 6 (4) |
Satisfied | 67 (45) | |
Neutral | 55 (37) | |
Dissatisfied | 16 (11) | |
Very dissatisfied | 5 (3) | |
Side effects (n, %) | Renal issues | 11 (7) |
Gastro-intestinal disturbances | 3 (2) | |
Cardiac problem | 4 (3) | |
Muscle pain | 2 (1) | |
Generalised weakness | 3 (2) | |
Others | 2 (1) | |
Not experienced | 124 (83) |